• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Fanapt Falls Flat! Link from the Street.com

Quote
Anonymous said:
This is probably a valid post. In the Vanda trials lack of efficacy was the key issue why Vanda could never get FDA approval. They turned over the data to Novartis who helped them massage it through the FDA. You have to wonder if there were some greased palms along the way!
Click to expand...

Fast forward to now. Fanapt is not selling because it is not being written. It was prescribed a little bit early on, but the lack of efficacy was seen after a month. It is a dead product.
 




Anonymous said:
I am curious. Who are the Nashville West Reps that are really bad? Also, are you aware that Herbert Meltzer (Father of Clozaril- the Psychiatrist that coined the term Atypical) pushed for Latuda to be on Formulary at Vanderbilt because he decided to leave this past year and go to Northwestern. Prior to this decision of his, he would not agree to speak for a Pharmaceutical company because Vanderbilt FORBIDS their MDs to speak or to attend any pharmaceutical program that is product specific. Are you also aware of the closed door rep policy for the Psych hospital. So, I suppose Dr. Meltzer is a better rep than the Nashville West Reps. As for your ignorance about the ability of the Nashville West Reps sales abilities- I believe they are consistently in the top of sales performance. I believe my 5 National awards is nothing to hang ones head over. Please do your research before you fly off the cuff about something you know nothing about. It's just plain wrong.
Click to expand...

FYI, Dr. Meltzer had nothing to do with Latuda getting on formulary.
He recused himself from having any part of the discussion. He did not present to P&T.

The reps did it on their own. They have access to the Hospital.
 












Loyal Novartis RD's and DM's have been running from this dog of a division for over a year now.

Then Lisa gets the boot and Now Debbie. Carol is charge and she is the one who brought this dog into our bags. Her days are numbered.

But then again we are all doomed in this BU. FXR has been keeping the lights on but it will be generic in Oct. Fanapt now budget is 79Mill almost double last yrs rev. and still puny for a 250 person FF.

Going to be a scary few months.
 








Inside news as of today. Fanapt will be divested. Vanda will retain marketing rights. Neuropsych Division will be completely eliminated since the prospects for the new antidepressant are nil.

Currently, there is nothing in the in license pipeline. Use your remaining time wisely and find a new job!
 




Anonymous said:
Loyal Novartis RD's and DM's have been running from this dog of a division for over a year now.

Then Lisa gets the boot and Now Debbie. Carol is charge and she is the one who brought this dog into our bags. Her days are numbered.

But then again we are all doomed in this BU. FXR has been keeping the lights on but it will be generic in Oct. Fanapt now budget is 79Mill almost double last yrs rev. and still puny for a 250 person FF.

Going to be a scary few months.
Click to expand...

At least 80 of us will be gone. I would not be shocked if it is even more.
 








































With a sick amount of budget given to us for the Quarter, I can't believe they are forcing us to promote this awful drug. Talk about going against compliance and buying our way in for access and increases VoS. Shame on you!!!
 












Top Bottom
Back
Quote